AMPA receptor potentiators for the treatment of CNS disorders

Current Drug Targets: CNS and Neurological Disorders

Volumn 3, Issue 3, 2004, Pages 181-194

  O'Neill, Michael J ^a   Bleakman, David ^a   Zimmerman, Dennis M ^a   Nisenbaum, Eric S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

AMPA receptor potentiator; BDNF; Cognition; CX 516; Cyclothiazide; Depression; Glutamate; LTP; LY404187; LY503430; Parkinson's disease

Indexed keywords

1 (1,3 BENZODIOXOL 5 YLCARBONYL)PIPERADINE; 2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; ANIRACETAM; BENZTHIAZIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; CX 546; CYCLOTHIAZIDE; DIAZOXIDE; GLUTAMIC ACID; LY 392098; LY 395163; LY 404187; LY 503430; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIN; OXIRACETAM; PIPERIDINE DERIVATIVE; PIRACETAM; PROTEIN KINASE LYN; PYRROLIDINE DERIVATIVE; RECEPTOR SUBUNIT; RNA; SULFONAMIDE; TETRAMER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGED; ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; BIOLOGICAL MODEL; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL STUDY; COGNITION; COGNITIVE DEFECT; CONVALESCENCE; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; FORCED SWIMMING TEST; GENETIC VARIABILITY; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEARNING; LONG TERM POTENTIATION; MEMORY; MENTAL DISEASE; MOLECULAR CLONING; MOLECULAR INTERACTION; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE STIMULATION; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PREDICTION; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; BENZOTHIADIAZINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID AGONISTS; HUMANS; NEURONAL PLASTICITY; PARKINSON DISEASE; PIPERIDINES; PYRROLIDINONES; RECEPTORS, AMPA;

EID: 3042843491     PISSN: 1568007X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568007043337508     Document Type: Review

References (135)

1. Parsons, C.; Danysz, W.; Lodge, D. In; Ionotropic Glutamate Receptors as Therapeutic Targets W. Danysz D. Lodge, C.G. Parsons, Ed, F.P. Graham Publishing Co.; Tennesse, 2002, pp 1-30.
2. Armstrong, N.; Sun, Y.; Chen, G.Q.; Gouaux, E. Nature, 1998, 395, 913-917.
3. Armstrong, N.; Gouaux, E. Neuron, 2000, 28, 165-181.
4. Hume, R.I.; Dingledine, R.; Heinemann, S.F. Science, 1991, 253, 1028-31.
5. Washburn, M.S.; Numberger, M.; Zhang, S.; Dingledine, R. J. Neurosci., 1997, 17, 9393-9406.
6. Lomeli, H.; Mosbacher, J.; Melcher, T.; Hoger, T.; Geiger, J.R.P.; Kuner, T.; Monyer, H.; Higuchi, M.; Bach, A.; Seeburg, P.H. Science, 1994, 266, 1709-1713.
7. Mosbacher, J.; Schoepfer, R.; Monyer, H.; Burnashev, N.; Seeburg, P.H.; Ruppersberg, J.P. Science 1994, 266, 1059-1062.
8. Monyer, H.; Seeburg, P.H.; Wisden, W. Neuron, 1991, 6, 799-810.
9. Sommer, B.; Keinanen, K.; Verdoorn, T.A.; Wisden, W.; Brunashev, N.; Herb, A.; Kohler, M.; Takagi, T.; Sakmann, B.; Seeburg, P.H. Science, 1990, 249, 1580-1584.
10. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. Pharmacol. Rev., 1999, 51, 7-61.
11. Yamada, K.A. Neurobiol. of Disease, 1998, 5, 67-80.
12. Ito, I.; Tanabe, S.; Kohda, A.; Sugiyama, H. J. Phsyiol., 1990, 424, 533-543.
13. Isaacson, J.; Nicoll, R. Proc. Natl. Acad. Sci. USA, 1991, 88, 10936-10940.
14. Osawa, S.; Iino, M.; Abe, M. Neurosci. Res., 1991, 12, 72-82.
15. Tang, C.; Shi, Q.; Katchman, A.; Lynch, G. Science, 1991, 254, 288-290.
16. Vyklicky, L.; Patneau, D.; Mayer, M. Neuron, 1991, 7, 971-894.
17. Copani, A.; Genazzani, A.; Aleppo, G.; Casabona, G.; Canonico, L.; Scapagnini, U.; Nicoletti, F. J. Neurochem., 1992, 58, 1199-1204.
18. Tsuzuki, K.; Takeuchi, T.; Ozawa, S. Mol. Brain Res., 1992, 16, 150-110.
19. Johansen, T.; Chaudhary, A.; Verdoorn, T. Mol. Pharmacol., 1995, 48, 946-955.
20. Partin, K.; Fleck, M.; Mayer, M. J. Neuroscience, 1996, 16, 6634-6647.
21. Fallarino, F.; Genazzani, A.; Silla, S.; L'Episcopo, M.; Camici, O.; Corazzi, L.; Nicoletti, F.; Fioretti, M. J. Neurochem., 1995, 65, 912-918.
22. Arai, A.; Lynch, G. Brain Res., 1998, 799, 230-234.
23. Arai, A.; Kessler, M.; Xiao, P.; Ambros-Ingerson, J.; Rogers, G.; Lynch, G. Brain Res., 1994, 638, 343-346.
24. Staubli, U.; Rogers, G.; Lynch, G. Proc. Natl. Acad. Sci. USA, 1994, 91, 777-781.
25. Desai, M.; Valli, M.; Monn, J.; Schoepp, D. Neuropharmacology, 1995, 34, 141-147.
26. Pittaluga, A.; Bonfanti, A.; Arvigo, D.; Raiteri, M. Naunyn-Schmiedeberg's Arch. Pharmacol., 1999, 359, 272-279.
27. Hennegriff, M.; Arai, A.; Kessler, M.; Vanderklish, M.; Mutneja, M.; Rogers, G.; Neve, R.; Lynch, G. J. Neurochem., 1997, 68, 2424-2434.
28. Arai, A.; Kessler, M.; Rogers, G.; Lynch, G. Mol. Pharmacol., 2000, 58, 802-813.
29. Ambros-Ingerson, J.; Lynch, G. Proc. Natl. Acad. Sci. USA, 1993, 90, 7903-7907.
30. Arai, A.; Guidotti, A.; Costa, E.; Lynch, G. Neuroreport, 1996, 7, 2211-2215.
31. Arai, A.; Kessler, M.; Ambros-Ingerson, J.; Quan, A.; Yigiter, E.; Rogers, G.; Lynch, G. Neuroscience, 1996, 75, 573-585.
32. Arai, A.; Xia, Y.; Kessler, M.; Phillips, D.; Chamberlin, R.; Granger, R.; Lynch, G. Mol. Pharmacol., 2002, 62, 566-577.
33. Arai, A.; Xia, Y.; Rogers, G.; Lynch, G.; Kessler, M. J. Pharmacol. Exp. Ther., 2002, 303, 1075-1085.
34. Yamada, K.; Rothman, S.M. J. Physiol., 1992, 458, 385-407.
35. Gates, M., Ogden, A., Bleakman, D. Neuropharmacology, 2001, 40, 984-991.
36. Patneau, D.; Vyklicky, L.; Mayer, M. J. Neurosci., 1993, 13, 3496-3509.
37. Pelletier, M.; Hablitz, J. J. Neurophysiol., 1994, 72, 1032-1036.
38. Rammes, G.; Parsons, C.; Muller, W.; Swandulla, D. Neurosci. Letters, 1994, 175, 21-24.
39. Trussell, L.; Zhang, S.; Raman, I. Neuron, 1993, 10, 1185-1193.
40. Yamada, K.; Tang, C. J. Neurosci., 1993, 3, 3904-3915.
41. Wong, L.; Mayer, M. Mol. Pharmacol, 1993, 44, 504-510.
42. Fleck, M.; Bahring, R.; Patneua, D.; Mayer, M. J. Neurophysiol., 1996, 75, 2322-2333.
43. Baumbarger, P.J.; Muhlhauser, M.; Yang, C.R.; Nisenbaum, E.S. Neuropharmacology, 2001, 40, 992-1002.
44. Desai, M.; Burnett, J.; Schoepp, D. J. Neurochem., 1994, 63, 231-237.
45. Bertolino, M.; Baraldi, M.; Parenti, C.; Braghiroli, D.; DiBella, M.; Vicini, S.; Costa, E. Receptor Channels, 1993, 1, 267-278.
46. Phillips, D.; Sonnenberg, J.; Arai, A.; Vaswani, R.; Krutzik, P.; Kleisli, T.; Kessler, M.; Granger, R.; Lynch, G.; Chamberlin, R. Bioorg. & Med. Chem., 2002, 10, 1229-1248.
47. Desos, P.; Serkiz, B.; Morain, P.; Lepagnol, J.; Cordi, A. Bioorg. Med. Chem. Lett., 1996, 6, 3003-3008.
48. Lepagnol, J.; Lebrun, C.; Pilliere, E.; Thomas, J.; Deso, P.; Cordi, A.; Lestage, P. Soc. Neurosci. Abstr., 1997, 23, 717.6.
49. Lockhart, B.; Fabrice, I.; Closier, M.; Lestage, P. Eur. J. Pharmacol., 2000, 401, 145-153.
50. Sekiguchi, M.; Fleck, M.; Mayer, M.; Takeo, J.; Chiba, Y.; Yamashita, S.; Wada, K. J. Neurosci., 1997, 17, 5760-5771.
51. Sekiguchi, M.; Nishakawa, K.; Aoki, S.; Wada, K. Brit. J. Pharmacol., 2002, 136, 1033-1041.
52. Miu, P.; Jarvie, K.; Radhakrishnan, V.; Gates, M.; Ogden, A.; Ornstein, P.; Zarrinmayeh, H.; Ho, K.; Peters, D.; Grabell, J.; Gupta, A.; Zimmerman, D.; Bleakman, D. Neuropharmacology, 2001, 40, 976-983.
53. Murray, T.K.; Whalley, K.; Robinson, C.; Ward, M.A.; Hicks, C.A.; Lodge, D.; Vandergriff, J.; Baumbarger, P.; Suida, E.; Gates, M.; Ogden, A.M.; Skolnick, P.; Zimmerman, D.M.; Nisenbaum, E.S.; Bleakman, D.; O'Neill, M.J. J. Pharmacol. Exp. Ther., 2003, 306, 752-762.
54. Baumbarger, P.J.; Muhlhauser, M.; Zhai, J.; Yang, C.R.; Nisenbaum, E.S. J. Pharmacol. Exp. Ther., 2001, 298, 86-102.
55. Quirk, J.; Nisenbaum, E. CNS Drug Rev., 2002, 8, 255-282.
56. Bliss, T.V.; Lomo, T. J. Physiol., 1973, 232, 331-356.
57. Bliss, T.V.; Collingridge, G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 1993, 361, 31-39.
58. Lynch, G.; Baudry, M. Science, 1984, 224, 1057-1063.
59. Malenka, R.C.; Nicoll, R.A. Science, 1999, 285, 1870-1874.
60. Mayer, M.L.; Westbrook, G.L. Nature, 1984, 309, 261-263.
61. Vandergriff, J.; Huff, K.; Bond, A.; Lodge, D. Neuropharmacology, 2001, 40, 1003-1009.
62. Staubli, U., Perez, Y.; Xu, F.; Rogers, G.; Ingvar, M.; Stone-Elander, S.; Lynch G. Proc. Natl. Acad. Sci. USA, 1994, 91, 11158-11162.
63. Pontecorvo, M.J.; Evans, H.L. Pharmacol. Biochem. Behav., 1985, 22, 745-752.
64. Verloes, R.; Scotto, A.M.; Gobert, J.; Wulfert, E. Psychopharmacology (Berl.), 1988, 95, 226-230.
65. Davies, C.M.; Moskovitz, B.; Nguyen, M.A.; Tran, B.B.; Arai, A.; Lynch, G.; Granger, R. Psychopharmacology (Berl.), 1997, 133, 161-167.
66. Granger, R.; Staubli, U.; Davis, M.; Perez, Y.; Nilsson, L.; Rogers, G.A.; Lynch, G. Synapse, 1993, 15, 326-329.
67. Granger, R.; Deadwyler, S.; Davis, M.; Moskovitz, B.; Kessler, M.; Rogers, G.; Lynch, G. Synapse, 1996, 22, 332-337.
68. Hampson, R.E.; Rogers, G.; Lynch, G.; Deadwyler, S.A. J. Neurosci., 1998, 18, 2740-2747.
69. Zivkovic, I.; Thompson, D.M.; Bertolino, M.; Uzunov, D.; DiBella, M.; Costa, E.; Guidotti, A. J. Pharmacol. Exp. Ther., 1995, 272, 300-309.
70. Thompson, D.M.; Guidotti, A.; DiBella, M.; Costa, E. Proc. Natl. Acad. Sci., 1995, 92, 7667-7671.
71. Fowler, J.; O'Neill, M.J.; McCulloch, J. Soc. Neurosci. Abstr., 2002, 540.2.
72. Dimond, S.J.; Scammell, R.E.; Pryce, I.G.; Huws, D.; Gray, C. Psychopharmacology, 1979, 64, 341-348.
73. Oepen, G.; Eisele, K.; Thoden, U.; Birg, W. Pharmacopsychiatry, 1985, 18, 343-346.
74. Ingvar, M.; Ambros-Ingerson, J.; Davis, M.; Granger, R.; Kessler, M.; Rogers, G.A.; Schehr, R.S.; Lynch, G. Exp. Neurol., 1997, 146, 553-559.
75. Goff, D.C.; Leahy, L.; Bermanm, I.; Posever, T.; Herz, L.; Leon, A.C.; Johnson, S.A.; Lynch, G. J. Clin. Psychopharm., 2001, 21, 484-487.
76. Wall, P.M.; Messier, C. Behav. Brain Res., 2001, 127, 99-117.
77. Tanji, J.; Hoshi, E. Current Opinion in Neurobiology, 2001, 11, 164-170.
78. Duncan, G.E.; Miyamoto, S.; Leipzig, J.N.; Lieberman, J.A. J. Pharmacol. Exp. Ther., 2000, 293, 8-14.
79. Duncan, G.E.; Moy, S.S.; Knapp, D.J.; Mueller, R.A.; Breese, G.R. Brain Res., 1998, 787, 181-90.
80. Hayashi, T.; Umemori, H.; Mishina, M.; Yamamoto, T. Nature, 1999, 397, 72-76.
81. Zafra, F.; Hengerer, B.; Leibrock, J.; Thoenen, H.; Lindholm, D. EMBO J., 1990, 9, 3545-3550.
82. Hardingham, G.E.; Cruzalegui, F.H.; Chawla, S.; Bading, H. Cell Calcium, 1998, 23, 131-134.
83. Tao, X.; Finkbeiner, S.; Arnold, D.B.; Shaywitz, A.J.; Greenberg, M.E. Neuron, 1998, 20, 709-726.
84. Zafra, F.; Lindholm, D.; Castren, E.; Hartikka, J.; Thoenen, H. J. Neurosci., 1992, 12, 4793-4799.
85. Legutko, B.; Li, X.; Skolnick, P. Neuropharmacology, 2001, 40, 1019-1027.
86. Lauterborn, J.C.; Lynch, G.; Vanderklish, P.; Arai, A.; Gall, C.M. J. Neurosci., 2000, 20, 8-21.
87. Mackowiak, M.; O'Neill, M.J.; Hicks, C.A.; Bleakman, D.; Skolnick, P. Neuropharmacology, 2002, 43, 1-10.
88. Bymaster, F.P.; McNamara, R.K.; Tran, P.V. Exp. Opin. Invest. Drugs, 2003, 12, 531-543.
89. Altar, C.A.; Boylan, C.B.; Jackson, C.; Hershenson, S.; Miller, J.; Wiegand, S.J.; Lindsay, R.M.; Hyman, C. Proc. Natl. Acad. Sci. USA, 1992, 89, 11347-11351.
90. Lapchak, P.A.; Beck, K.D.; Araujo, D.M.; Irwin, I.; Langston, J.W.; Hefti, F. Neuroscience, 1993, 53, 639-650.
91. Sauer, H.; Fischer, W.; Nikkhah, G.; Wiegand, S.J.; Brundin, P.; Lindsay, R.M.; Bjorklund, A. Brain Res., 1993, 626, 37-44.
92. Siuciak, J.; Altar, C.; Wiegand, S.; Lindsay, R. Brain Res., 1994, 633, 326-330.
93. Siuciak, J.A.; Boylan, C.; Fritsche, M.; Altar, C.A.; Lindsay, R.M. Brain Res., 1996, 710, 11-20.
94. Vaidya, V.A.; Siuciak, J.A.; Du, F.; Duman, R.S. Neuroscience, 1999, 89, 157-66.
95. Duman, R.; Malberg, J.; Nakagawa, S. J. Pharmacol. Exp. Ther., 2001, 299, 401-407.
96. Mamounas, L.; Blue, M.; Siuciak, J.; Altar, C. J. Neurosci., 1996, 15, 7929-7939.
97. Dowlatshahi, D.; MacQueen, G.M.; Wang, J.F.; Young, L.T. Lancet, 1998, 352, 1754-5.
98. Bayer, T.A.; Schramm, M.; Feldmann, N.; Knable, M.B.; Falkai, P. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2000, 24, 881-8.
99. Tao, X.; Finkbeiner, S.; Arnold, D.; Shaywitz, A.; Greenberg, M. Neuron, 1998, 20, 709-726.
100. Chen, B.; Dowlatshahi, D.; MacQueen, G.M.; Wang, J.F.; Young, L.T. Biol. Psychiatry, 2001, 50, 260-5.
101. Nibuya, M.; Nestler, E.; Duman, R. J. Neurosci., 1996, 16, 2365-2372.
102. Frechilla, D.; Otano, A.; Del Rio, J. Progress in NeuroPsychopharmacology and Biol. Psychiatry, 1998, 22, 787-802.
103. Nibuya, M.; Morinobu, S.; Duman, R. J. Neurosci., 1995, 15, 7539-7547.
104. Duman, R.S.; Heninger, G.R.; Nestler, E.J. Archives of General Psychiatry, 1997, 54, 597-606.
105. Skolnick, P. Eur. J. Pharmacol., 1999, 375, 31-40.
106. Russo-Neustadt, A.A.; Beard, R.C.; Huang, Y.M.; Cotman, C.W. Neuroscience, 2000, 101, 305-312.
107. Zetterstrom, T.; Pei, Q.; Ainsworth, K.; Grahame-Smith, D. British J. Pharmacol., 1998, 123, 106.
108. Altar, C. Trends Phamacol. Sci., 1999, 20, 59-61.
109. Duman, R.S. Biol. Psychiatry, 1998, 44, 324-335.
110. Siuciak, J.; Lewis, D.; Wiegand, S.; Lindsay, R. Pharmacol. Biochem. Behav., 1997, 56, 131-137.
111. Brandoli, C.; Sanna, A.; De Bernardi, M.A.; Follesa, P.; Brooker, G.; Mocchetti, I. J. Neurosci., 1998, 18, 7953-61.
112. Smith, M.; Makino, S.; Altemus, M.; Michelson, D.; Hong, S.-K.; Kvetnansky, R.; Post, R. Proc. Natl. Acad. Sci. USA, 1995, 92, 8788-8792.
113. Russo-Neustadt, A.; Ha, T.; Ramirez, R.; Kesslak, J.P. Behav. Brain Res., 2001, 120, 87-95.
114. Duman, R.; Malberg, J.; Thome, J. Biol. Psychiatry, 1999, 46, 1181-1191.
115. Sheline, Y.I.; Wang, P.W.; Gado, M.H.; Csernansky, J.G.; Vannier, M.W. Proc. Natl. Acad. Sci. USA, 1996, 93, 3908-3913.
116. Neeper, S.A.; Gomez-Pinilla, F.; Choi, J.; Cotman, C.W. Brain Res., 1996, 726, 49-56.
117. Shirayama, Y.; Chen, A.C.; Nakagawa, S.; Russell, D.S.; Duman, R.S. J. Neurosci., 2002, 22, 3251-61.
118. Li, X.; Tizzano, J.P.; Griffey, K.; Clay, M.; Lindstrom, T.; Skolnick, P. Neuropharmacology, 2001, 40, 1028-1033.
119. Li, X.; Witkin, J.M.; Nead, A.B.; Skolnick, P. Cellular and Molecular Neurobiology, 2003, 23, 419-430.
120. Bai, F.; Bergeron, M.; Nelson, D.L. Neuropharmacology, 2003, 44, 1013-1021.
121. O'Neill, M.J.; Siemers, E.R. Exp. Rev. Neurotherapeutics, 2002, 2, 89-104.
122. Homykiewicz, O.; Kish, S.J. Adv. Neurol., 1987, 45, 19-34.
123. Hughes, A.J.; Ben-Schlomo, Y.; Daniel, S.E.; Lees, A.J. Neurology, 1992, 42, 1142-1146.
124. Zigmond, M.J.; Stricker, E.M. Int. Rev. Neurobiol., 1989, 31, 1-79.
125. Nakajima, K.; Hida, H.; Shimano, Y.; Fugimoto, I.; Hashitani, T.; Kumazaki, M.; Sakurai, T.; Nishino, H. Brain Res., 2001, 916, 76-84.
126. Gash, D.M.; Zhang, Z.; Ovadia, A.; Cass, W.A.; Yi, A.; Simmerman, L.; Russell, D.; Martin, D.; Lapchak, P.A.; Collins, F.; Hoffer, B.J.; Gerhardt, G.A. Nature, 1996, 380, 252-255.
127. Rosenbald, C.; Kirik, D.; Bjorklund, A. Exp. Neurol., 2000, 161, 503-516.
128. Benowitz, L.I.; Routtenberg, A. Trends Neurosci., 1997, 20, 84-91.
129. Namgung, U.; Routtenberg, A. Eur. J. Neurosci., 2000, 12, 3124-3136.
130. Lynch, G.; Granger, R.; Ambros-Ingerson, J.; Davis, M.C.; Kessler, M.; Schehr, R. Exp. Neurol., 1997, 145, 89-92.
131. Segovia, G.; Porras, A.; Del Arco, A.; Mora, F. Mechanims Ageing Dev., 2001, 122, 1-29.
132. Carlsson, A.; Hansson, L.O.; Waters, N.; Carlsson, M.L. Br. J. Psychiatry, 1999, S37, 2-6.
133. Tamminga, C.A. Crit. Rev. Neurobiol., 1998, 12, 21-36.
134. Lee, C.R.; Benfield, P. Drugs & Aging, 1994, 4, 257-273.
135. Jhee, S.S.; Chappell, A.S.; Shiovitz, T.S.; Kim, E.; Toublanc, N.; Culter, N.R. Soc. Neurosci. Abstr., 2002, 94.14.